| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mustafa K Shehata, Assem A Ismail, Maher A Kame. Combined Donepezil with Astaxanthin via Nanostructured Lipid Carriers Effective Delivery to Brain for Alzheimer's Disease in Rat Model. International journal of nanomedicine. vol 18. 2023-08-03. PMID:37534058. |
donepezil (dpl), a specific acetylcholinesterase inhibitor, is used as a first-line treatment to improve cognitive deficits in alzheimer's disease (ad) and it might have a disease modifying effect. |
2023-08-03 |
2023-08-14 |
rat |
| Xu-Fei Chen, Shan-Shan Li, Yu-Jun Bai, Ze-Feng Zhao, Ya-Jun Bai, Gu Gong, Xi-Rui He, Xiao-Hui Zhen. Design and synthesis of ligustrazine derivatives as potential anti-Alzheimer's agents. Natural product research. 2023-07-28. PMID:37505222. |
a novel series of ligustrazine derivatives was designed, synthesized, and evaluated as acetylcholinesterase (ache) and butylcholinesterase (buche) inhibitors for the treatment of alzheimer's disease (ad). |
2023-07-28 |
2023-08-14 |
Not clear |
| Victoria Richmond, Bruno N Falcone, Marta S Maier, Pau Arroyo Máñe. Putting the Puzzle Together To Get the Whole Picture: Molecular Basis of the Affinity of Two Steroid Derivatives to Acetylcholinesterase. ACS omega. vol 8. issue 28. 2023-07-24. PMID:37483177. |
alzheimer's disease (ad) is a progressive neurodegenerative disorder that has no cure because its etiology is still unknown, and its main treatment is the administration of acetylcholinesterase (ache) inhibitors. |
2023-07-24 |
2023-08-14 |
Not clear |
| Sowmya Andole, Husna Sd, Srija Sudhula, Lavanya Vislavath, Hemanth Kumar Boyina, Kiran Gangarapu, Vasudha Bakshi, Krishna Prasad Devarakond. 3D QSAR based Virtual Screening of Flavonoids as Acetylcholinesterase Inhibitors. Advances in experimental medicine and biology. vol 1424. 2023-07-24. PMID:37486499. |
in an attempt to develop therapeutic agents to treat alzheimer's disease, a series of flavonoid analogues were collected, which already had established acetylcholinesterase (ache) enzyme inhibition activity. |
2023-07-24 |
2023-08-14 |
Not clear |
| Yan-Jun Li, Cai-Cai Liang, Ling Jin, Juan Che. Inhibition mechanisms of four ellagitannins from terminalia chebula fruits on acetylcholinesterase by inhibition kinetics, spectroscopy and molecular docking analyses. Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy. vol 302. 2023-07-15. PMID:37453379. |
acetylcholinesterase (ache) is an important therapeutic target for the treatment of alzheimer's disease (ad), and the development of natural ache inhibitors as candidates has played a significant role in drug discovery. |
2023-07-15 |
2023-08-14 |
Not clear |
| Ana Matošević, Dejan M Opsenica, Marta Spasić, Nikola Maraković, Antonio Zandona, Suzana Žunec, Marija Bartolić, Zrinka Kovarik, Anita Bosa. Evaluation of 4-aminoquinoline derivatives with an n-octylamino spacer as potential multi-targeting ligands for the treatment of Alzheimer's disease. Chemico-biological interactions. 2023-07-05. PMID:37406982. |
the most successful therapeutic strategy in the treatment of alzheimer's disease (ad) is directed toward increasing levels of the neurotransmitter acetylcholine (ach) by inhibition of acetylcholinesterase (ache) and butyrylcholinesterase (bche), the enzymes responsible for its hydrolysis. |
2023-07-05 |
2023-08-14 |
human |
| Géssica Oliveira Mendes, Samuel Silva da Rocha Pita, Paulo Batista de Carvalho, Michel Pires da Silva, Alex Gutterres Taranto, Franco Henrique Andrade Leit. Molecular Multi-Target Approach for Human Acetylcholinesterase, Butyrylcholinesterase and Pharmaceuticals (Basel, Switzerland). vol 16. issue 6. 2023-06-28. PMID:37375827. |
molecular multi-target approach for human acetylcholinesterase, butyrylcholinesterase and alzheimer's disease (ad) is a neurodegenerative condition characterized by progressive memory loss and other affected cognitive functions. |
2023-06-28 |
2023-08-14 |
human |
| Ana Paula Murray, Brunella Biscussi, Valeria Cavallaro, Martina Donozo, Silvana A Rodrigue. Naturally Occurring Cholinesterase Inhibitors from Plants, Fungi, Algae, and Animals: A Review of the Most Effective Inhibitors Reported in 2012-2022. Current neuropharmacology. 2023-06-26. PMID:37357520. |
since the development of the "cholinergic hypothesis" as an important therapeutic approach in the treatment of alzheimer's disease (ad), the scientific community has made a remarkable effort to discover new and effective molecules with the ability to inhibit the enzyme acetylcholinesterase (ache). |
2023-06-26 |
2023-08-14 |
Not clear |
| Mohammad Hossein Asgarshamsi, Mehrdad M Dehkordi, Afshin Fassih. Design, Synthesis, Molecular Docking, and Molecular Dynamics Simulation Studies of novel 3-Hydroxypyridine-4-One Derivatives as Potential Acetylcholinesterase Inhibitors. Chemistry & biodiversity. 2023-06-22. PMID:37347200. |
researchers have focused on inhibiting acetylcholinesterase for alzheimer's disease treatment. |
2023-06-22 |
2023-08-14 |
Not clear |
| Shangfu Li, Dian Teguh, Depeng Wu, Lesong Liu, Chaofeng Hu, Jinbo Yuan, Charles A Inderjeeth, Jiake X. Antidementia medication acetylcholinesterase inhibitors have therapeutic benefits on osteoporotic bone by attenuating osteoclastogenesis and bone resorption. Journal of cellular physiology. 2023-06-19. PMID:37334837. |
this study was designed to determine whether the use of acetylcholinesterase inhibitors (acheis), a group of drugs that stimulate acetylcholine receptors and are used to treat alzheimer's disease (ad), is associated with osteoporosis protection and inhibition of osteoclast differentiation and function. |
2023-06-19 |
2023-08-14 |
mouse |
| Lindsay H Burns, Zhe Pei, Hoau-Yan Wan. Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development. Drug development research. 2023-06-09. PMID:37291958. |
the decades-old cholinergic hypothesis of alzheimer's disease (ad) led to clinical testing and fda approval of acetylcholinesterase inhibitor drugs. |
2023-06-09 |
2023-08-14 |
Not clear |
| Arman Abdalla Ali, Shakhawan Ahmad Mhamad, Aso Hameed Hasan, Iqrar Ahmad, Siti Awanis Abdullah, Shajarahtunnur Jamil, Harun Patel, Sankaranarayanan Murugesan, Joazaizulfazli Jamali. Synthesis, biological evaluation and molecular modeling studies of modulated benzyloxychalcones as potential acetylcholinesterase inhibitors. Journal of biomolecular structure & dynamics. 2023-06-09. PMID:37293930. |
acetylcholinesterase inhibitors (acheis) have become a significant target in the search for an efficient treatment of alzheimer's disease. |
2023-06-09 |
2023-08-14 |
Not clear |
| Shipra Nagar, Maria Pigott, Wirginia Kukula-Koch, Helen Sherida. Unravelling Novel Phytochemicals and Anticholinesterase Activity in Irish Molecules (Basel, Switzerland). vol 28. issue 10. 2023-05-27. PMID:37241886. |
unravelling novel phytochemicals and anticholinesterase activity in irish acetylcholinesterase inhibitors remain the mainstay of symptomatic treatment for alzheimer's disease. |
2023-05-27 |
2023-08-14 |
Not clear |
| Manal Abdel Fattah Ezzat, Sara Mohamed Abdelhamid, Marwa A Fouad, Hatem A Abdel-Aziz, Heba Abdelrasheed Alla. Design, synthesis, in vitro, and in vivo evaluation of novel phthalazinone-based derivatives as promising acetylcholinesterase inhibitors for treatment of Alzheimer's disease. Drug development research. 2023-05-27. PMID:37243322. |
design, synthesis, in vitro, and in vivo evaluation of novel phthalazinone-based derivatives as promising acetylcholinesterase inhibitors for treatment of alzheimer's disease. |
2023-05-27 |
2023-08-14 |
mouse |
| Pratap G Kenchappa, Yalpi Karthik, Poornima D Vijendra, Raghavendra L S Hallur, Ajay S Khandagale, Ashok K Pandurangan, Sathisha G Jayanna, Mohammed Ali Alshehri, Abdulrahman Alasmari, Samy Sayed, Manjula Shantaram, Muntazir Mushta. Frontiers in pharmacology. vol 14. 2023-05-26. PMID:37234712. |
alzheimer's disease (ad) is a type of neurodegenerative disease, associated with the hastening of ros, acetylcholinesterase (ache) activity, and amyloid β peptides plaques in the brain. |
2023-05-26 |
2023-08-14 |
Not clear |
| Yassir Boulaamane, Pallavi Kandpal, Anshuman Chandra, Mohammed Reda Britel, Amal Maurad. Chemical library design, QSAR modeling and molecular dynamics simulations of naturally occurring coumarins as dual inhibitors of MAO-B and AChE. Journal of biomolecular structure & dynamics. 2023-05-18. PMID:37199265. |
additionally, a multi-stage virtual screening combining qsar modeling, molecular docking, and admet prediction was conducted against monoamine oxidase b and acetylcholinesterase, two relevant targets known for their neuroprotective properties and 'disease-modifying' potential in parkinson's and alzheimer's disease. |
2023-05-18 |
2023-08-14 |
Not clear |
| Fatemeh Pishgouii, Safa Lotfi, Ebrahim Sedaghat. Anti-AChE and Anti-BuChE Screening of the Fermentation Broth Extracts from Twelve Aspergillus Isolates and GC-MS and Molecular Docking Studies of the Most Active Extracts. Applied biochemistry and biotechnology. 2023-05-02. PMID:37129742. |
nowadays, the administration of cholinesterase enzyme (acetylcholinesterase: ache and butyrylcholinesterase: buche) inhibitors is very common for the symptomatic treatment of alzheimer's disease and the other forms of dementia and cns disorders. |
2023-05-02 |
2023-08-14 |
Not clear |
| Münteha Girgin, Sevim Isik, Nigar Kantarci-Carsibas. Proposing novel natural compounds against Alzheimer's disease targeting acetylcholinesterase. PloS one. vol 18. issue 4. 2023-04-27. PMID:37104478. |
proposing novel natural compounds against alzheimer's disease targeting acetylcholinesterase. |
2023-04-27 |
2023-08-14 |
Not clear |
| Kandrakonda Yelamanda Rao, Shaik Jeelan Basha, Kallubai Monika, Navya Naidu Gajula, Irla Sivakumar, Sandeep Kumar, Ramakrishna Vadde, Bindu Madhava Reddy Aramati, Rajagopal Subramanyam, Amooru Gangaiah Dam. Development of quinazolinone and vanillin acrylamide hybrids as multi-target directed ligands against Alzheimer's disease and mechanistic insights into their binding with acetylcholinesterase. Journal of biomolecular structure & dynamics. 2023-04-26. PMID:37098803. |
development of quinazolinone and vanillin acrylamide hybrids as multi-target directed ligands against alzheimer's disease and mechanistic insights into their binding with acetylcholinesterase. |
2023-04-26 |
2023-08-14 |
Not clear |
| Aravind Ayyolath, Anoop Kallingal, Varun Thachan Kundil, Akshay Maniyeri Suresh, E Jayadevi Variya. Investigating the disease-modifying properties of sclerotiorin in Alzheimer's therapy using acetylcholinesterase inhibition. Chemical biology & drug design. 2023-04-19. PMID:37076430. |
investigating the disease-modifying properties of sclerotiorin in alzheimer's therapy using acetylcholinesterase inhibition. |
2023-04-19 |
2023-08-14 |
Not clear |